Cargando…
Engineering Archeal Surrogate Systems for the Development of Protein–Protein Interaction Inhibitors against Human RAD51
Protein–protein interactions (PPIs) are increasingly important targets for drug discovery. Efficient fragment-based drug discovery approaches to tackle PPIs are often stymied by difficulties in the production of stable, unliganded target proteins. Here, we report an approach that exploits protein en...
Autores principales: | Moschetti, Tommaso, Sharpe, Timothy, Fischer, Gerhard, Marsh, May E., Ng, Hong Kin, Morgan, Matthew, Scott, Duncan E., Blundell, Tom L., R. Venkitaraman, Ashok, Skidmore, John, Abell, Chris, Hyvönen, Marko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117717/ https://www.ncbi.nlm.nih.gov/pubmed/27725183 http://dx.doi.org/10.1016/j.jmb.2016.10.009 |
Ejemplares similares
-
Small-Molecule Inhibitors That Target Protein–Protein Interactions in the RAD51 Family of Recombinases
por: Scott, Duncan E, et al.
Publicado: (2015) -
Structure‐activity relationship of the peptide binding‐motif mediating the BRCA2:RAD51 protein–protein interaction
por: Scott, Duncan E., et al.
Publicado: (2016) -
ATP half‐sites in RadA and RAD51 recombinases bind nucleotides
por: Marsh, May E., et al.
Publicado: (2016) -
A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death
por: Scott, Duncan E., et al.
Publicado: (2021) -
Using a Fragment-Based Approach To Target Protein–Protein Interactions
por: Scott, Duncan E, et al.
Publicado: (2013)